Several high-profile cases have spotlighted the pharmaceutical industry’s penchant for aggressively marketing their products, often pushing legal and ethical boundaries. While some practices genuinely aim at informing healthcare providers about new and effective medications, others deliberately tilt towards promoting off-label uses of drugs and even, in some instances, suppressing information related to potential risks. When caught, pharma companies are often fined – but the pivotal question arises: are these fines substantive enough to deter future malpractices?